MorphoSys AG (MOR.F)

20,88 -0,37 (-1,74%) Börsenschluss: 03:15PM CEST

MorphoSys AG

Semmelweisstrasse 7
Planegg 82152
Germany
49 89 89927 0
https://www.morphosys.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 648

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jean-Paul Kress M.D.	Chairman of Management Board, MD & CEO	1,94M	N/A	1965
Mr. Sung H. Lee	CFO & Member of Management Board	488,7k	N/A	1970
Dr. Malte Peters M.D.	Chief R&D Officer and Member of the Management Board	1,15M	N/A	1962
Dr. Marlies Sproll	Special Adviser to the Chief Exec. Officer	N/A	N/A	1958
Mr. Klaus De Wall	Head of Accounting & Tax	N/A	N/A	N/A
Ms. Lara Smith Weber	Head of Controlling, Corp. Fin. & Corp. Devel.	N/A	N/A	N/A
Dr. Margit Urban	Head of Discovery Alliances & Technologies	N/A	N/A	N/A
Dr. Anja Pomrehn	Sr. VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Charlotte Lohmann	Sr. VP of Legal, Compliance & IP and Gen. Counsel	N/A	N/A	1970
Mr. Thomas Biegi	VP & Head of Corp. Communications	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Corporate Governance

MorphoSys AGs ISS Governance QualityScore, Stand 31. Juli 2022, lautet 1. Die grundlegenden Scores sind Audit: 5, Vorstand: 1, Shareholderrechte: 1, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.